Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-06-27
2006-06-27
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S045000, C424S046000, C424S084000, C424S085100, C424S085200, C424S085400, C424S085500, C424S085600, C424S085700, C424S178100, C424S809000, C514S002600, C514S008100, C530S387300, C530S391100, C530S866000
Reexamination Certificate
active
07067129
ABSTRACT:
The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.
REFERENCES:
patent: 4261973 (1981-04-01), Lee et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4902495 (1990-02-01), Kaliner et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5120525 (1992-06-01), Goldenberg
patent: 5169627 (1992-12-01), Cunningham-Rundles
patent: 5277894 (1994-01-01), Strauss et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5354934 (1994-10-01), Pitt et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5609846 (1997-03-01), Goldenberg
patent: 5658762 (1997-08-01), Zanetti et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5726044 (1998-03-01), Lo et al.
patent: 5843397 (1998-12-01), Goldenberg
patent: 6126938 (2000-10-01), Guy et al.
patent: 2002/0192222 (2002-12-01), Blumberg et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2004/0063912 (2004-04-01), Blumberg et al.
patent: 8821725 (1989-03-01), None
patent: 2045869 (1991-06-01), None
patent: 2045869 (1991-12-01), None
patent: 0 305 967 (1987-02-01), None
patent: 0 580 171 (1994-01-01), None
patent: WO 86/06635 (1986-11-01), None
patent: WO 91/07987 (1991-06-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 91/08773 (1991-06-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/19660 (1993-10-01), None
patent: WO 93/20834 (1993-10-01), None
patent: WO 93/21906 (1993-11-01), None
patent: WO 94/14437 (1994-07-01), None
patent: WO 94/15635 (1994-07-01), None
patent: WO 96/22024 (1996-07-01), None
patent: 9834645 (1998-08-01), None
patent: WO 98/34645 (1998-08-01), None
patent: WO 99/04813 (1999-02-01), None
Ahouse et al., J Immunol 151:6076-6088 (1993).
Berryman et al., J Histochem Cytochem 38(2):159-170 (1990).
Borel H et al., J Immunol Methods 126:159-168 (Sep. 20, 1990).
Burmeister WP et al., Nature 372:379-383 (1994).
Canfield et al., J Exp Med 173:1483-1491 (1991).
Czerkinsky et al., Infect Immun 57:1072-1077 (1989).
Dertzbaugh et al., CRC Press:119-131 (1990).
Elson et al., J Immunol 132:2736-2741 (1984).
Elson et al., J Immunol 133:2892-2897 (1984).
Elson et al., J Immunol 135:930-932 (1985).
Farges R et al., FEBS Lett 335 (3):305-308 (Oct. 12, 1993).
Fridman WH, FASEB J 5(12):2684-2690 (Sep. 1991).
Fritsche et al., J Allergy Clin Immunol 93:778-786 (1994).
Ghetie V et al., Immunology Today 18(12):592 (Dec. 1997).
Gosselin EJ et al., J Immunol 149:3477-3481 (1992).
Guyer et al., J Immunol 117:587-593 (1976).
Huber et al., Mol Biol 230:1077-1083 (1993).
International Search Report—PCT/US98/15395.
Israel et al., J. Immunol 154(12):6246-6251 (Jun. 15, 1995).
Kobayashi et al., J Immunol 146:68-74 (1991).
Langermann et al., J Exp Med 180:2277-2286 (1994).
Langermann et al., Nature 372:552-555 (1994).
Lencer WI et al., J Cell Biol 117:1197-1209 (1992).
Lencer WI et al., J Clin Invest 92:2941-2951 (1993).
Lund et al., J Immunol 147:2657-2662 (1991).
Mikael N et al., Lupus 3:173-179 (1994).
Mostov et al., Cell 43:389-390 (1985).
Patel et al., FEBS Lett 234(2):321-325 (1988).
Paul WF (ed)., Fundamental Immunology, 4th edition, pp. 1399-1401 (1999).
Rabinovich NR et al., Science 265:1401-1404 (1994).
Raghavan M et al., Immunity 1:303-315 (Jul. 1994).
Service RF, Science 265:1522-1524 (1994).
Simister NE et al., Nature 337:184-187 (1989).
Simister NE, American Society of Microbiology Press, Washington, DC pp. 57-73 (1990).
Squire CM et al., J Immunol 152:4388-4396 (1994).
Story CM et al., J Exp Med 180:2377-2381 (1994).
Supplementary Search Report—EP 96 90 3522.
Woof et al., Mol Immunol 23:319-330 (1986).
Kim JK et al., Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor.Eur J Immunol. Oct. 24, 1994;(10):2429-34.
Blumberg Richard S.
Lencer Wayne I.
Simister Neil E.
Brandeis University
Saunders David
The Brigham and Woman's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Receptor specific transepithelial transport in therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor specific transepithelial transport in therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor specific transepithelial transport in therapeutics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678889